Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
$8.70
-5.0%
$7.59
$5.65
$10.45
$319.56M1.08393,653 shs168,595 shs
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$17.90
-4.4%
$17.74
$5.95
$62.75
$1.38B1.04925,153 shs538,586 shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$32.43
-1.8%
$46.18
$22.85
$60.08
$1.34B0.46465,893 shs271,467 shs
Septerna, Inc. stock logo
SEPN
Septerna
$31.15
-0.7%
$26.15
$9.85
$32.63
$1.41B2.39312,056 shs211,653 shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
+0.22%-7.38%+36.31%+18.96%+19.27%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
+2.46%+0.21%+10.05%+3.54%-63.33%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
+3.93%+3.80%-41.25%-31.05%+37.84%
Septerna, Inc. stock logo
SEPN
Septerna
+2.68%+1.03%+30.00%+9.00%+214.64%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
$8.70
-5.0%
$7.59
$5.65
$10.45
$319.56M1.08393,653 shs168,595 shs
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$17.90
-4.4%
$17.74
$5.95
$62.75
$1.38B1.04925,153 shs538,586 shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$32.43
-1.8%
$46.18
$22.85
$60.08
$1.34B0.46465,893 shs271,467 shs
Septerna, Inc. stock logo
SEPN
Septerna
$31.15
-0.7%
$26.15
$9.85
$32.63
$1.41B2.39312,056 shs211,653 shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
+0.22%-7.38%+36.31%+18.96%+19.27%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
+2.46%+0.21%+10.05%+3.54%-63.33%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
+3.93%+3.80%-41.25%-31.05%+37.84%
Septerna, Inc. stock logo
SEPN
Septerna
+2.68%+1.03%+30.00%+9.00%+214.64%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
2.71
Moderate Buy$15.4077.01% Upside
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
2.38
Hold$23.8533.22% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.14
Hold$38.8019.64% Upside
Septerna, Inc. stock logo
SEPN
Septerna
2.80
Moderate Buy$43.1338.44% Upside

Current Analyst Ratings Breakdown

Latest FENC, MLTX, SEPN, and PAHC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/25/2026
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
UpgradeStrong SellHold
5/22/2026
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
Boost Price TargetBuy$13.00 ➝ $16.00
5/21/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
DowngradeStrong-BuyHold
5/14/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Lower Price TargetNeutral$62.00 ➝ $44.00
5/13/2026
Septerna, Inc. stock logo
SEPN
Septerna
Reiterated RatingBuy$40.00
5/12/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Reiterated RatingSell (E+)
5/12/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Boost Price TargetBuy$25.00 ➝ $30.00
5/11/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Boost Price TargetBuy$40.00 ➝ $45.00
5/8/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
DowngradeBuy (B)Buy (B-)
5/1/2026
Septerna, Inc. stock logo
SEPN
Septerna
Initiated CoverageBuy$43.00
4/21/2026
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
Reiterated RatingSell (D-)
(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
$44.64M6.80N/AN/A$1.04 per share8.37
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/A$4.27 per shareN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.30B1.01$3.21 per share10.11$7.05 per share4.60
Septerna, Inc. stock logo
SEPN
Septerna
$45.95M30.56N/AN/A$8.53 per share3.65
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
-$9.74M-$0.29N/A9.46N/A-17.12%-43.87%-11.35%8/13/2026 (Estimated)
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$227.32M-$3.87N/AN/AN/AN/A-85.15%-60.52%8/4/2026 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$48.26M$2.3313.929.770.506.35%37.14%8.57%6/30/2026 (Confirmed)
Septerna, Inc. stock logo
SEPN
Septerna
-$48.88M-$0.81N/AN/AN/A-49.88%-12.72%-8.87%8/10/2026 (Estimated)

Latest FENC, MLTX, SEPN, and PAHC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2026Q1 2026
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
-$0.02$0.01+$0.03$0.01$13.90 million$15.11 million
5/12/2026Q1 2026
Septerna, Inc. stock logo
SEPN
Septerna
-$0.4167-$0.19+$0.2267-$0.19$16.98 million$26.52 million
5/11/2026Q1 2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$0.91-$0.98-$0.07-$0.98N/AN/A
5/6/2026Q3 2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.72$0.76+$0.04$0.59$367.02 million$383.54 million
3/24/2026Q4 2025
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
$0.0423-$0.17-$0.2123-$0.17$14.75 million$13.78 million
3/24/2026Q4 2025
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
$0.03-$0.17-$0.20-$0.17$14.73 million$13.78 million
3/9/2026Q4 2025
Septerna, Inc. stock logo
SEPN
Septerna
-$0.23-$0.24-$0.01-$0.24$20.44 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
N/AN/AN/AN/AN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.48%N/A20.60%N/A
Septerna, Inc. stock logo
SEPN
Septerna
N/AN/AN/AN/AN/A

Latest FENC, MLTX, SEPN, and PAHC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/5/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.121.51%6/3/20266/3/20266/24/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
N/A
6.98
6.78
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
0.39
8.60
8.60
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.97
3.17
1.26
Septerna, Inc. stock logo
SEPN
Septerna
N/A
4.71
4.71

Institutional Ownership

CompanyInstitutional Ownership
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
55.51%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
93.85%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
Septerna, Inc. stock logo
SEPN
Septerna
N/A

Insider Ownership

CompanyInsider Ownership
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
10.73%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
12.02%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
50.13%
Septerna, Inc. stock logo
SEPN
Septerna
4.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
1034.89 million30.99 millionOptionable
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
273.61 million64.77 millionOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2,47540.56 million20.23 millionOptionable
Septerna, Inc. stock logo
SEPN
Septerna
N/A45.08 million43.14 millionN/A

Recent News About These Companies

Septerna (SEPN) Stock Forecast & Price Target
Septerna, Inc. ($SEPN) CEO 2025 Pay Revealed
Septerna Begins Phase 1 Trial of Oral SEP-479

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adherex Technologies stock logo

Adherex Technologies NASDAQ:FENC

$8.70 -0.46 (-5.02%)
Closing price 04:00 PM Eastern
Extended Trading
$8.70 0.00 (-0.06%)
As of 05:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

MoonLake Immunotherapeutics stock logo

MoonLake Immunotherapeutics NASDAQ:MLTX

$17.90 -0.82 (-4.38%)
Closing price 04:00 PM Eastern
Extended Trading
$17.93 +0.03 (+0.17%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$32.43 -0.61 (-1.85%)
Closing price 04:00 PM Eastern
Extended Trading
$32.39 -0.04 (-0.14%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Septerna stock logo

Septerna NASDAQ:SEPN

$31.15 -0.22 (-0.70%)
Closing price 04:00 PM Eastern
Extended Trading
$31.16 +0.01 (+0.02%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body. Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately one-third of all U.S. Food and Drug Administration (FDA) approved drugs, representing approximately 500 products with combined global revenue of approximately $125 billion in 2023. Despite the pharmacological and commercial success of GPCR-targeted agents, about 75% of potential GPCR therapeutic targets remain undrugged and, for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. Each step in GPCR activation involves subtle conformational changes that have been historically challenging to reproduce outside of a cell. The inability to isolate GPCR proteins in their native functional form outside of a cellular context has prevented scientists from leveraging some of the state-of-the-art technologies that have revolutionized drug discovery in other major target classes over the past decade. This complex challenge has limited GPCR drug discovery, particularly the development of novel oral small molecules, such as agonists (which activate GPCR signaling) for peptide GPCRs and allosteric modulators (which either increase or decrease the degree of GPCR activation by endogenous ligands). Our proprietary Native Complex Platform™ replicates the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time. Our foundational technologies enable us to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. We then apply state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging our platform, we conduct GPCR oral small molecule drug discovery using an industrialized and iterative structure-based drug design approach for a diverse collection of GPCR targets. Our Native Complex PlatformTM is designed to enable us to target specific GPCRs, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists (which inhibit GPCR signaling), and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects. We are advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline, is focused initially on three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. We intend to evaluate opportunities in other major therapeutic areas, such as neurology, women's health, cardiovascular, and respiratory disease. --- Leveraging our team, scientific and technical advisors, and our proprietary Native Complex Platform™, we aim to be a leader in the development of oral GPCR-targeted medicines for patients with significant unmet needs. We were incorporated under the laws of the State of Delaware in December 2019 under the name GPCR NewCo, Inc. and changed our name to Septerna, Inc. in June 2021. Our principal executive offices are located at 250 East Grand Avenue, South San Francisco, California.